An investigation of CYP2D6 genotype and response to metoprolol CR/XL during dose titration in patients with heart failure: A MERIT-HF substudy

Clinical Pharmacology and Therapeutics

Volumn 95, Issue 3, 2014, Pages 321-330

  Batty, J A ^a   Hall, A S ^b   White, H L ^b   Wikstrand, J ^c   De Boer, R A ^d   Van Veldhuisen, D J ^d   Van Der Harst, P ^d   Waagstein, F ^c   Hjalmarson, A ^c   Kjekshus, J ^c   Balmforth, A J ^b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC BETA-ANTAGONISTS; AGED; BLOOD PRESSURE; CHRONIC DISEASE; CYTOCHROME P-450 CYP2D6; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GENOTYPE; HEART FAILURE; HEART RATE; HEMODYNAMICS; HUMANS; MALE; METOPROLOL; MIDDLE AGED; RISK FACTORS; STEREOISOMERISM; TREATMENT OUTCOME;

EID: 84894463808     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.193     Document Type: Article

References (44)

1. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353, 2001-2007 (1999).
2. Poole-Wilson, P.A. et al.; Carvedilol Or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362, 7-13 (2003).
3. CIBIS-II Investigators. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353, 9-13 (1999).
4. McMurray, J.J. et al.; ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 33, 1787-1847 (2012).
5. Hunt, S.A. et al.; American College of Cardiology Foundation; American Heart Association. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J. Am. Coll. Cardiol. 53, e1-e90 (2009).
6. Lindenfeld, J. et al.; Heart Failure Society of America. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J. Card. Fail. 16, e1-194 (2010).
7. Hjalmarson, A. et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 283, 1295-1302 (2000).
8. Cleland, J.G. et al.; IMPROVEMENT of Heart Failure Programme Committees and Investigators. Improvement programme in evaluation and management; Study Group on Diagnosis of the Working Group on Heart Failure of The European Society of Cardiology. Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey. Lancet 360, 1631-1639 (2002).
9. Gottlieb, S.S. et al.; MERIT-HF Investigators. Tolerability of beta-blocker initiation and titration in the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Circulation 105, 1182-1188 (2002).
10. Wikstrand, J. et al.; MERIT-HF Study Group. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF). J. Am. Coll. Cardiol. 40, 491-498 (2002).
11. Basile, J.N. Titration of beta-blockers in heart failure. How to maximize benefit while minimizing adverse events. Postgrad. Med. 113, 63-70; quiz 3 (2003).
12. Follath, F., Cleland, J.G., Klein, W. & Murphy, R. Etiology and response to drug treatment in heart failure. J. Am. Coll. Cardiol. 32, 1167-1172 (1998).
13. Yamada, T. et al. Which subgroup of patients with dilated cardiomyopathy would benefit from long-term beta-blocker therapy? A histologic viewpoint. J. Am. Coll. Cardiol. 21, 628-633 (1993).
14. Eichhorn, E.J., Heesch, C.M., Risser, R.C., Marcoux, L. & Hatfield, B. Predictors of systolic and diastolic improvement in patients with dilated cardiomyopathy treated with metoprolol. J. Am. Coll. Cardiol. 25, 154-162 (1995).
15. Shin, J. & Johnson, J.A. Beta-blocker pharmacogenetics in heart failure. Heart Fail. Rev. 15, 187-196 (2010).
16. Lennard, M.S., Silas, J.H., Freestone, S., Ramsay, L.E., Tucker, G.T. & Woods, H.F. Oxidation phenotype-a major determinant of metoprolol metabolism and response. N. Engl. J. Med. 307, 1558-1560 (1982).
17. Lennard, M.S., Tucker, G.T. & Woods, H.F. The polymorphic oxidation of betaadrenoceptor antagonists. Clinical pharmacokinetic considerations. Clin. Pharmacokinet. 11, 1-17 (1986).
18. McGourty, J.C., Silas, J.H., Lennard, M.S., Tucker, G.T. & Woods, H.F. Metoprolol metabolism and debrisoquine oxidation polymorphism-population and family studies. Br. J. Clin. Pharmacol. 20, 555-566 (1985).
19. Regardh, C.G. & Johnsson, G. Clinical pharmacokinetics of metoprolol. Clin. Pharmacokinet. 5, 557-569 (1980).
20. Reiter, M.J. Cardiovascular drug class specificity: beta-blockers. Prog. Cardiovasc. Dis. 47, 11-33 (2004).
21. Gattis, W.A. Metoprolol CR/XL in the treatment of chronic heart failure. Pharmacotherapy 21, 604-613 (2001).
22. Johnson, J.A. & Burlew, B.S. Metoprolol metabolism via cytochrome P4502D6 in ethnic populations. Drug Metab. Dispos. 24, 350-355 (1996).
23. Brodde, O.E. & Kroemer, H.K. Drug-drug interactions of beta-adrenoceptor blockers. Arzneimittelforschung. 53, 814-822 (2003).
24. Zanger, U.M., Raimundo, S. & Eichelbaum, M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch. Pharmacol. 369, 23-37 (2004).
25. Bradford, L.D. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 3, 229-243 (2002).
26. Terra, S.G. et al. beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure. Clin. Pharmacol. Ther. 77, 127-137 (2005).
27. Wuttke, H. et al. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects. Clin. Pharmacol. Ther. 72, 429-437 (2002).
28. Zineh, I. et al. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin. Pharmacol. Ther. 76, 536-544 (2004).
29. Fux, R. et al. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study. Clin. Pharmacol. Ther. 78, 378-387 (2005).
30. Bijl, M.J. et al. Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users. Clin. Pharmacol. Ther. 85, 45-50 (2009).
31. Rau, T. et al. Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study. Clin. Pharmacol. Ther. 85, 269-272 (2009).
32. Blake, C.M., Kharasch, E.D., Schwab, M. & Nagele, P. A Meta-Analysis of CYP2D6 Metabolizer Phenotype and Metoprolol Pharmacokinetics. Clin. Pharmacol. Ther. 94, 394-399 (2013).
33. Cleland, J.G., Gemmell, I., Khand, A. & Boddy, A. Is the prognosis of heart failure improving? Eur. J. Heart Fail. 1, 229-241 (1999).
34. White, H.L. et al.; MERIT-HF Study Group. An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study. Eur. J. Heart Fail. 5, 463-468 (2003).
35. Savva, J. et al.; Merit-HF Study Group. Polymorphisms of adrenoceptors are not associated with an increased risk of adverse event in heart failure: a MERIT-HF substudy. J. Card. Fail. 15, 435-441 (2009).
36. Sachse, C., Brockmoller, J., Bauer, S. & Roots, I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am. J. Hum. Genet. 60, 284-295 (1997).
37. Raimundo, S. et al. A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects. Clin. Pharmacol. Ther. 76, 128-138 (2004).
38. Kirchheiner, J. et al. Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Ther. 76, 302-312 (2004).
39. Rau, T. et al. Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment. Pharmacogenetics 12, 465-472 (2002).
40. Clark, D.W., Morgan, A.K. & Waal-Manning, H. Adverse effects from metoprolol are not generally associated with oxidation status. Br. J. Clin. Pharmacol. 18, 965-967 (1984).
41. Brown, M.A. et al. Polymorphisms of the CYP2D6 gene increase susceptibility to ankylosing spondylitis. Hum. Mol. Genet. 9, 1563-1566 (2000).
42. Beyeler, C., Armstrong, M., Bird, H.A., Idle, J.R. & Daly, A.K. Relationship between genotype for the cytochrome P450 CYP2D6 and susceptibility to ankylosing spondylitis and rheumatoid arthritis. Ann. Rheum. Dis. 55, 66-68 (1996).
43. Ervik, M., Kylberg-Hanssen, K. & Johansson, L. Determination of metoprolol in plasma and urine using high-resolution gas chromatography and electroncapture detection. J. Chromatogr. 381, 168-174 (1986).
44. Koch, W.H. Technology platforms for pharmacogenomic diagnostic assays. Nat. Rev. Drug Discov. 3, 749-761 (2004).